Companies Grace Therapeutics, Inc.
Grace Therapeutics (GRCE): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Grace Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,084,971FY2025
- $1,270,820FY2026
CEO total pay was $1,270,820 in fiscal 2026, up from $1,084,971 in fiscal 2025.
FY2026: salary $579,000 · bonus $0 · stock awards $0 · option awards $391,820
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Prashant Kohli | $579,000 | $0 | $0 | $391,820 | $289,500 | $0 | $10,500 | $1,270,820 |
| Chief Executive Officer | ||||||||
| Amresh Kumar | 310,000 | 0 | 0 | 52,150 | 93,000 | 0 | 10,500 | 465,650 |
| Vice President, Program Management | ||||||||
| Carrie D’Andrea | 310,000 | 0 | 0 | 52,150 | 93,000 | 0 | 10,500 | 465,650 |
| Former Vice President, Clinical Operations | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Prashant Kohli | $1,270,820 | $1,084,971 | — | ↑ +185,849 |
| Amresh Kumar | 465,650 | 431,913 | — | ↑ +33,737 |
| Carrie D’Andrea | 465,650 | 431,913 | — | ↑ +33,737 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The executive compensation program is intended to attract, motivate and retain high-performing senior executives, encourage and reward superior performance, and align the executives’ interests with those of the Company and stockholders by providing compensation that is competitive with comparable companies, rewarding the achievement of annual objectives through bonuses, and providing long-term incentives through the grant of stock options.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Amresh Kumar | Option | 3,500 | 2.64 | — |
| Carrie D’Andrea | Option | 3,500 | 2.64 | — |
| Amresh Kumar | Option | 8,225 | 2.96 | — |
| Carrie D’Andrea | Option | 8,225 | 2.96 | — |
| Prashant Kohli | Option | 17,361 | 2.64 | — |
| Amresh Kumar | Option | 22,500 | 2.08 | — |
| Carrie D’Andrea | Option | 22,500 | 2.08 | — |
| Prashant Kohli | Option | 53,654 | 2.96 | — |
| Prashant Kohli | Option | 169,051 | 2.08 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Vimal KavuruIndependent · Board Chair · Compensation (Chair) · Nominating and Corporate Governance | $99,000 | — | $25,467 | — | — | $124,467 |
| A. Brian DavisIndependent · Compensation · Nominating and Corporate Governance · Audit (Chair) | 64,000 | — | 25,467 | — | — | 89,467 |
| Edward NeugeborenIndependent · Compensation · Nominating and Corporate Governance · Audit | 56,000 | — | 25,467 | — | — | 81,467 |
| S. George KottayilIndependent | 40,000 | — | 25,467 | — | — | 65,467 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $25,467 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $259,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $259,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Grace Therapeutics as a peer
Companies that benchmark against GRCE
No companies currently name GRCE as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Grace Therapeutics, Inc. | 2026 | Prashant Kohli | $579,000 | $0 | $391,820 | $289,500 | $1,270,820 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (10 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Prashant Kohli. DEF 14A, filed 2026-07-28. Section “Executive Compensation”. As printed: 1,270,820. View filing ↗
- Section 01, Amresh Kumar. DEF 14A, filed 2026-07-28. Section “Executive Compensation”. As printed: 465,650. View filing ↗
- Section 01, Carrie D’Andrea. DEF 14A, filed 2026-07-28. Section “Executive Compensation”. As printed: 465,650. View filing ↗
- Section 08, Vimal Kavuru. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 124,467. View filing ↗
- Section 08, A. Brian Davis. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 89,467. View filing ↗
- Section 08, Edward Neugeboren. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 81,467. View filing ↗
- Section 08, S. George Kottayil. DEF 14A, filed 2026-07-28. Section “Director Compensation”. As printed: 65,467. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 259,000 + equity 0 + all other 0 = 259,000, summed across the director compensation table rows.
- Grace Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-07-28. CEO total compensation as printed in Grace Therapeutics, Inc.'s own proxy. As printed: 1,270,820. View filing ↗